Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for follicular lymphoma
The disease accounts for up to 30% of all non-Hodgkin lymphoma cases
Read More
May 16, 2024 | News, Regulatory
The disease accounts for up to 30% of all non-Hodgkin lymphoma cases
Read MoreMay 16, 2024 | News, Regulatory
Approximately half of the global population is at risk of mosquito-borne viral disease
Read MoreMay 15, 2024 | News, Regulatory
The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration
Read MoreMay 15, 2024 | News, Regulatory
More than 13,000 people are diagnosed with cervical cancer every year in the US
Read MoreMay 14, 2024 | News, Regulatory
The deadline to submit ahead of the 25th WHO Expert Committee meeting is 1 November 2024
Read MoreMay 13, 2024 | News, Regulatory
Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy
Read MoreMay 13, 2024 | News, Regulatory
Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year
Read MoreMay 9, 2024 | News, Regulatory
It is estimated that 1.27 million global deaths in 2019 were caused by antibiotic-resistant infections
Read MoreMay 8, 2024 | News, Regulatory
The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria
Read MoreMay 8, 2024 | News, Healthcare, Regulatory
The company applied to voluntarily withdraw its European marketing authorisation on 5 March
Read MoreMay 7, 2024 | News, Regulatory
About 4,000 people in England with the genetic blood disorder are expected to benefit from the decision
Read MoreMay 3, 2024 | News, Regulatory
The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting
Read MoreAccount Specialist - Respiratory - Kent & Medway
Territory Sales Manager - North London & East Anglia
Account Specialist - Respiratory - Nottingham